Aug 20, 2025 8:30am EDT RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025
Aug 14, 2025 4:05pm EDT RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review
Aug 06, 2025 8:30am EDT RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire
Jul 28, 2025 8:30am EDT RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors
Jul 14, 2025 8:30am EDT RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET
May 15, 2025 4:05pm EDT RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights
May 14, 2025 8:30am EDT RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st
May 06, 2025 8:30am EDT U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform
May 01, 2025 8:30am EDT RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
Apr 29, 2025 8:30am EDT Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial
